Dr Joanneke Overbeek, a pharmacist at Radboud University Medical Center in Nijmegen, the Netherlands, presented the outcomes of a multicenter trial comparing the standard dose of 160 mg once daily of enzalutamide with a reduced dose of 120 mg once daily in frail prostate cancer patients. The study found that the reduced dose of enzalutamide appeared to reduce cognitive side effects and fatigue without compromising efficacy, providing valuable insights for optimizing treatment in this patient population.
With the educational support of:
